Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Aclaris Therapeutics (ACRS) over the last 6 years, with Q3 2025 value amounting to $3.1 million.

  • Aclaris Therapeutics' Treasury Shares rose 86.97% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 86.97%. This contributed to the annual value of $2.1 million for FY2024, which is 3772.89% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Treasury Shares of $3.1 million as of Q3 2025, which was up 86.97% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Treasury Shares ranged from a high of $3.2 million in Q1 2025 and a low of $1.4 million during Q1 2022
  • Moreover, its 5-year median value for Treasury Shares was $1.7 million (2023), whereas its average is $2.1 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 505533.14% in 2021, then plummeted by 4155.23% in 2022.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Treasury Shares stood at $1.5 million in 2021, then rose by 2.09% to $1.5 million in 2022, then rose by 0.08% to $1.5 million in 2023, then skyrocketed by 37.73% to $2.1 million in 2024, then skyrocketed by 47.82% to $3.1 million in 2025.
  • Its Treasury Shares stands at $3.1 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.2 million for Q1 2025.